Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Summary

The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.

Timeline

Start

2021-10-28

Primary completion

2024-11-08

Completion

2024-12-13

Publications

• Khawaja MR, Jameson G, Cridebring D, Shannon P, Han H, Moore J, Von Hoff D, Posner RG, Hlavacek WS, Kolch W, Kholodenko BN, Rukhlenko OS, Roe DJ, Wertheim BC, Borazanci E. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. J Immunother Precis Oncol. 2026 Feb 10;9(1):17-24. doi: 10.36401/JIPO-25-20. eCollection 2026 Feb.

Drugs

Indications